Table 2 All-cause death and adverse events
| Â | Treatment and control | Patients included in analysis | All cause death (N,) | Drug related adverse events (N) |
|---|---|---|---|---|
Arturi2016 | Liraglutide | 10 | 0 | 0 |
Sitagliptin | 10 | 0 | 0 | |
Insulin glargine | 12 | 0 | 0 | |
Jorsal2016 | Liraglutide | 122 | 1 | AE (cardiac = 13, gastrointestinal = 80*, CNS = 38*, other = 38(31.1%)), SAE (cardiac = 12, gastrointestinal = 0, CNS = 2, other = 13) |
Placebo | 119 | 0 | AE (cardiac = 10, gastrointestinal = 19, CNS = 15, other = 38), SAE (cardiac = 3, gastrointestinal = 1, CNS = 3, other = 9) | |
Lepore2016 | Albiglutide | 27 | 0 | AE = 20, SAE = 0 |
Placebo | 30 | 0 | AE = 25, SAE = 4 | |
Margulies2016 | Liraglutide | 154 | 19 | Cardiac = 37; glycemic = 36; other = 35 |
Placebo | 146 | 16 | Cardiac = 34; glycemic = 28; other = 52 |